Larry Lo
Impact in
- Immunology top 10%
- Atherosclerosis and Cardiovascular Diseases
- Hematology top 10%
Papers in
- Surgery 4
- Management of metastatic bone disease 3
-
- Erythropoietin and Anemia Treatment 2
- Iron Metabolism and Disorders 2
- Co-authors
- Matt Devalaraja (5 shared papers)Michael Davidson (3 shared papers)Pablo E. Pérgola (2 shared papers)Douglas Kling (3 shared papers)Florian M.M. Baeres (1 shared paper)Mads D.M. Engelmann (1 shared paper)Milana Ivkovic (1 shared paper)Dominic S. Raj (1 shared paper)
- Journals
- International Journal of Radiation Oncology*Biology*Physics (2 papers)Journal of the American Society of Nephrology (1 paper)Clinical Cancer Research (1 paper)Circulation (1 paper)Haemophilia (1 paper)
- Partner nations
- United StatesNetherlandsItaly
In The Last Decade
Larry Lo
17 papers receiving 1.3k citations
Larry Lo's Hit Papers
Peers
Comparison fields: 5 of 83
- Immunology 370
- Hematology 98
- Biotechnology 80
- Nephrology 54
- Molecular Biology 555
Countries citing papers authored by Larry Lo
This map shows the geographic impact of Larry Lo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry Lo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry Lo more than expected).
Fields of papers citing papers by Larry Lo
This network shows the impact of papers produced by Larry Lo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry Lo. The network helps show where Larry Lo may publish in the future.
Co-authors
The 25 scholars most cited alongside Larry Lo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial Hit paper breakdown → | 2021 | 475 |
| 2 | 2009 | 232 | |
| 3 | 2008 | 169 | |
| 4 | 2008 | 145 | |
| 5 | 2010 | 125 | |
| 6 | 2020 | 58 | |
| 7 | 2019 | 21 | |
| 8 | 2020 | 21 | |
| 9 | 2006 | 20 | |
| 10 | 2014 | 17 | |
| 11 | 2006 | 14 | |
| 12 | 2020 | 9 | |
| 13 | A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies. | 2005 | 6 |
| 14 | 2011 | 6 | |
| 15 | Abstract 13727: Effects of Ziltivekimab (ZILTI), a Novel Anti-Interleukin-6 Monoclonal Antibody, on Markers of Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease on Hemodialysis | 2019 | 3 |
| 16 | 2021 | 1 | |
| 17 | 2021 | 1 | |
| 18 | 2025 | 0 | |
| 19 | 2019 | 0 |
About Larry Lo
Larry Lo is a scholar working on Surgery, Hematology, Molecular Biology, Nephrology and Pulmonary and Respiratory Medicine, having authored 19 papers that have together received 1.3k indexed citations. Recurring topics across this work include Management of metastatic bone disease (3 papers), Erythropoietin and Anemia Treatment (2 papers), Iron Metabolism and Disorders (2 papers), Dialysis and Renal Disease Management (2 papers), IL-33, ST2, and ILC Pathways (2 papers), Hermeneutics and Narrative Identity (1 paper), Blood properties and coagulation (1 paper) and Vitamin K Research Studies (1 paper). The work is most often cited by research in Immunology (370 citations), Hematology (98 citations), Biotechnology (80 citations), Nephrology (54 citations) and Molecular Biology (555 citations). Larry Lo has collaborated with scholars based in United States, Netherlands and Italy. Frequent co-authors include Matt Devalaraja, Michael Davidson, Pablo E. Pérgola, Douglas Kling, Florian M.M. Baeres, Mads D.M. Engelmann, Milana Ivkovic, Dominic S. Raj, Paul M. Ridker and Peter Libby. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Journal of the American Society of Nephrology, Clinical Cancer Research, Circulation and Haemophilia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.